{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:40:56Z","timestamp":1792449656977,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejmech.2023.115977","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:35:16Z","timestamp":1700872516000},"page":"115977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD\/F691L"],"prefix":"10.1016","volume":"264","author":[{"given":"Xiuqi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Anna","family":"DeFilippis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsigereda","family":"Weldemichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Gunaganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuc","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuet-Kin","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9212-2010","authenticated-orcid":false,"given":"Hong-yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115977_bib1","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115977_bib2","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/leu.2014.55","article-title":"Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients","volume":"28","author":"Kihara","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2023.115977_bib3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115977_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0092-8674(02)00741-9","article-title":"The conformational plasticity of protein kinases","volume":"109","author":"Huse","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115977_bib5","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/jm501603h","article-title":"Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors","volume":"58","author":"Vijayan","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115977_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115977_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1097-2765(03)00505-7","article-title":"The structural basis for autoinhibition of FLT3 by the juxtamembrane domain","volume":"13","author":"Griffith","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2023.115977_bib8","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.4081\/oncol.2012.e8","article-title":"An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment","volume":"6","author":"Grafone","year":"2012","journal-title":"Onco Rev."},{"key":"10.1016\/j.ejmech.2023.115977_bib9","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115977_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115977_bib11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2023.115977_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121177","article-title":"Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220)","volume":"10","author":"Zorn","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115977_bib13","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115977_bib14","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/jm9007533","article-title":"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1 ,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor","volume":"52","author":"Chao","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115977_bib15","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","article-title":"Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial","volume":"19","author":"Cortes","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2023.115977_bib16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2023.115977_bib17","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1182\/blood-2018-01-821629","article-title":"Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115977_bib18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.673.673","volume":"120","author":"Levis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115977_bib19","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1016\/j.bmcl.2009.07.024","article-title":"Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors","volume":"19","author":"Patel","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115977_bib20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115977_bib21","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2014-10-605808","article-title":"Secondary mutations as mediators of resistance to targeted therapy in leukemia","volume":"125","author":"Daver","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115977_bib22","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115977_bib23","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors","volume":"29","author":"Smith","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2023.115977_bib24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115977_bib25","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","article-title":"Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)","volume":"96","author":"Nagel","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejmech.2023.115977_bib26","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/2159-8290.CD-15-0060","article-title":"Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 \"gatekeeper\" F691L mutation with PLX3397","volume":"5","author":"Smith","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2023.115977_bib27","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115977_bib28","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1\u20132 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2023.115977_bib29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","article-title":"Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia","volume":"35","author":"Mori","year":"2017","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2023.115977_bib30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00894-022-05254-0","article-title":"Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy","volume":"28","author":"Zhou","year":"2022","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.ejmech.2023.115977_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejmech.2015.02.052","article-title":"Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors","volume":"94","author":"Frett","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115977_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113776","article-title":"Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor","volume":"225","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115977_bib33","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03445","article-title":"Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy","volume":"3","author":"Warkentin","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2023.115977_bib34","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.3324\/haematol.2014.117028","article-title":"Inhibition of c-Kit by tyrosine kinase inhibitors","volume":"100","author":"Galanis","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2023.115977_bib35","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","volume":"131","author":"Yamaura","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115977_bib36","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1021\/acs.jmedchem.1c01792","article-title":"Identification of 2-Aminopyrimidine derivatives as FLT3 kinase inhibitors with high selectivity over c-KIT","volume":"65","author":"Tong","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115977_bib37","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1021\/acs.jmedchem.0c02247","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115977_bib38","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1021\/acs.jmedchem.1c00459","article-title":"Identification of thieno[3,2-d]pyrimidine derivatives as dual inhibitors of focal Adhesion kinase and FMS-like tyrosine kinase 3","volume":"64","author":"Cho","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115977_bib39","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.3390\/ijms20225739","article-title":"Design and synthesis of 4-(heterocyclic substituted amino)-1H-Pyrazole-3-Carboxamide derivatives and their potent activity against acute myeloid leukemia (AML)","volume":"20","author":"Zhi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115977_bib40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejmech.2019.05.021","article-title":"Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model","volume":"176","author":"Heng","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115977_bib41","doi-asserted-by":"crossref","first-page":"115448","DOI":"10.1016\/j.ejmech.2023.115448","article-title":"Rational design of 4-((6-phenoxypyrimidin-4-yl)amino)-N-(4-(piperazin-1-yl)phenyl)-1H-pyrazole-3-carboxamide (LT-540-717) as orally bioavailable FLT3 inhibitor","volume":"256","author":"Zhi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115977_bib42","doi-asserted-by":"crossref","first-page":"14664","DOI":"10.1021\/acs.jmedchem.1c01196","article-title":"Discovery of a potent FLT3 inhibitor (LT-850-166) with the capacity of overcoming a variety of FLT3 mutations","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423009443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423009443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:00:09Z","timestamp":1759330809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423009443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":42,"alternative-id":["S0223523423009443"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115977","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD\/F691L","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115977","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115977"}}